Who owns Attovia Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ATTO from SEC Form 13F filings across 10 reporting managers. All positions are from one synchronized reporting period — 2019-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2019-06-30 reporting period, 10 institutions disclosed 1.3M shares of Attovia Therapeutics, Inc. worth $0; the largest disclosed holder is Tyrian Investments, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
10
13F holders
$0
value, 2026 filers
1.3M
shares disclosed
0
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2019-06-30 · % of fund = share of the manager's own book · % of co. = share of ATTO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Tyrian Investments, L.P. | 342,800 | $2.9M | 1.1% | — | — |
| 2 | BLACKROCK ADVISORS LLC | 258,100 | $2.0M | 0.0% | — | — |
| 3 | Balter Liquid Alternatives, LLC | 361,674 | $901,000 | 0.4% | — | — |
| 4 | BlackRock Group LTD | 102,700 | $786,000 | 0.0% | — | — |
| 5 | Edinburgh Partners Ltd | 98,500 | $768,000 | 0.4% | — | — |
| 6 | BlackRock Investment Management, LLC | 33,500 | $256,000 | 0.0% | — | — |
| 7 | TFS CAPITAL LLC | 16,472 | $184,000 | 0.1% | — | — |
| 8 | LUCUS ADVISORS LLC | 14,821 | $116,000 | 0.2% | — | — |
| 9 | Jump Trading, LLC | 18,264 | $66,000 | 0.0% | — | — |
| 10 | FNY Partners Fund LP | 6,500 | $50,000 | 0.0% | — | — |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.